ID   21MT-2
AC   CVCL_7932
SY   21-MT-2; 21MT2
DR   Cell_Model_Passport; SIDM01901
DR   DepMap; ACH-002401
DR   GEO; GSM1172935
DR   GEO; GSM1172847
DR   GEO; GSM3145687
DR   IARC_TP53; 21721
DR   PharmacoDB; 21MT2_9_2019
DR   Wikidata; Q54583258
RX   DOI=10.1007/978-1-4612-0411-4_18;
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   PubMed=1977518;
RX   PubMed=7923592;
RX   PubMed=8482634;
RX   PubMed=24176112;
RX   PubMed=25960936;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: JWGray breast cancer cell line panel.
CC   Characteristics: 21PT is non-tumorigenic whereas 21NT and 21MT-1/21-MT-2 cause tumors in the nude mice system.
CC   Doubling time: 42.0 +- 2.5 hours (Note=In alpha H&E medium), 42.3 +- 4.7 hours (Note=In D medium) (PubMed=8482634).
CC   HLA typing: A*26:01,31:01; B*35:02,38:01; C*04:01,12:03; DRB1*04:03,04:03 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser33Phefs*9 (c.96_97insT); Zygosity=Unspecified (PubMed=7923592).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7931 ! 21MT-1
OI   CVCL_7933 ! 21NT
OI   CVCL_7934 ! 21PT
OI   CVCL_IP81 ! H16F1
OI   CVCL_IP82 ! H16N-2
OI   CVCL_IP83 ! H16N-3
SX   Female
AG   37Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 22
RX   DOI=10.1007/978-1-4612-0411-4_18;
RA   Band V., Sager R.;
RT   "Tumor progression in breast cancer.";
RL   (In) Neoplastic transformation in human cell system. Mechanism of carcinogenesis; Rhim J.S., Dritschilo A. (eds.); pp.169-178; Humana Press; New York (1990).
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994).
RX   PubMed=1977518;
RA   Band V., Zajchowski D., Swisshelm K.L., Trask D.K., Kulesa V., Cohen C.,
RA   Connolly J.L., Sager R.;
RT   "Tumor progression in four mammary epithelial cell lines derived from
RT   the same patient.";
RL   Cancer Res. 50:7351-7357(1990).
RX   PubMed=7923592; DOI=10.1093/carcin/15.9.1969;
RA   Liu X.-L., Band H., Gao Q.-S., Wazer D.E., Chu Q.-M., Band V.;
RT   "Tumor cell-specific loss of p53 protein in a unique in vitro model of
RT   human breast tumor progression.";
RL   Carcinogenesis 15:1969-1973(1994).
RX   PubMed=8482634; DOI=10.1016/0360-3016(93)90176-V;
RA   Wazer D.E., Joyce M., Jung L., Band V.;
RT   "Alterations in growth phenotype and radiosensitivity after
RT   fractionated irradiation of breast carcinoma cells from a single
RT   patient.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 26:81-88(1993).
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).